News

Oculogica’s EyeBOX is the only objective diagnostic cleared by the US FDA and Australia TGA as an aid in diagnosis of concussion.   New York, NY- May 4, 2021—Oculogica, a medical device company and leader in concussion diagnosis and categorization, announced today the Therapeutic Goods Administration (TGA) of Australia granted approval to its EyeBOX technology. …

Australia’s TGA Grants Approval to First Objective Concussion Diagnostic Read More »

Oculogica, the leader in non-invasive assessment of concussion, announces today the granting of U.S. Patent No. 10,863,902 by the U.S. Patent and Trademark Office. This patent protects Oculogica’s method and system for assessing glaucoma in a patient using a noninvasive eye tracking system.

Oculogica Founder, Dr. Uzma Samadani and CEO, Dr. Rosina Samadani, join the 11th annual list of women and men from such companies as Netflix, Google, and Patagonia, as well as institutions such as Johns Hopkins University and the ACLU of Massachusetts.

Last year, the FDA granted authorization for commercial use of the first tool that provides an objective diagnosis of concussions. Called EyeBox, it was developed by sisters Uzma and Rosina Samadani.

Watch our EyeBOX technology featured in Trevor Noah’s and Microsoft President Brad Smith’s discussion with Green Bay Packers President & CEO Mark Murphy.

Midwest Orthopaedics at Rush (MOR) is the first in Illinois to offer a new eye-tracking technology to more quickly identify a patient with ocular changes after a potential concussion or traumatic brain injury.

TitletownTech today announced it has invested in Oculogica, an innovative digital health company, by leading an $8 million round of funding that recently closed.

A venture fund led by the Green Bay Packers and Microsoft has invested in a new technology that promises to provide a major advance in the diagnosis of concussions.

From the age of six, Dr. Uzma Samadani, MD, Ph.D, knew she wanted to be a doctor.

Oculogica, Inc., a pioneer in algorithm-based neuro-diagnostics for brain health, announced today that the American Medical Association (AMA) has confirmed the addition of a new Category 3 CPT Code, 0X17T, Eye movement analysis test without spatial calibration, allowing clinicians to appropriately report the services related exclusively to the Oculogica EyeBOX® exam.